MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semerg.2026.102779

Медицинская библиотека · Semergen · 2026

[Study of the association between metabolic liver disease and renal function impairment: an updated systematic review and meta-analysis of prospective studies (2020-2025)].

Salcedo Joven I, Fernández Ramos A, Cinza Sanjurjo S

СтатьяСистематический обзорМетаанализАннотация на английскомПеревод в очереди

Аннотация

Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) are highly prevalent conditions that share pathophysiological mechanisms. The possible bidirectional association between these diseases has gained increasing relevance, particularly due to the prognostic role of liver fibrosis in renal outcomes. This systematic review aims to update the current knowledge on this topic. A systematic review was conducted following the PRISMA 2020 guidelines. The literature search was performed in PubMed, Scopus, and Web of Science, covering the period from August 2020 to February 2025, without language restrictions. Prospective studies with at least 12 months of follow-up were included, enrolling adults with MASLD diagnosed by imaging techniques or validated non-invasive indices. Renal outcomes of interest were reduced glomerular filtration rate (GFR <60mL/min/1.73 m2) or albuminuria (≥30mg/g). Study selection and analysis were performed by a single reviewer, which represents a potential limitation due to the increased risk of selection bias. Data were systematically extracted and synthesized, focusing on the incidence, prevalence, and progression of CKD in patients with MASLD. A meta-analysis was subsequently performed using the inverse-variance method under a fixed-effects model, and results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical heterogeneity was assessed using Cochran's Q test (X2) and quantified with the I2 statistic. Eighteen studies met the inclusion criteria. Most reported a positive association between MASLD and incident CKD. Liver fibrosis was consistently identified as a key determinant, significantly increasing the risk of renal impairment and accelerating its progression. The prevalence of CKD was higher in patients with MASLD compared to individuals without the condition. However, in the quantitative analysis heterogeneity was generally high, reflecting methodological and clinical differences among the included studies. MASLD is associated with an increased risk and faster progression of CKD, particularly in the presence of advanced fibrosis. These findings highlight the need for early identification of renal damage in MASLD patients and support the integration of non-invasive fibrosis assessment tools into clinical practice. However, the results should be interpreted with caution due to the substantial heterogeneity observed.

Для цитирования: Salcedo Joven I, Fernández Ramos A, Cinza Sanjurjo S. [Study of the association between metabolic liver disease and renal function impairment: an updated systematic review and meta-analysis of prospective studies (2020-2025)].. Semergen. 2026. DOI: 10.1016/j.semerg.2026.102779.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.